These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8707164)

  • 41. In vitro and in vivo characterization of a reversible synthetic heparin analog.
    Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
    Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio.
    Javot L; Lecompte T; Rabiskova M; Maincent P
    J Control Release; 2009 Oct; 139(1):8-14. PubMed ID: 19470393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy?
    Andrassy K; Eschenfelder V
    Thromb Res; 1996; 81(2 Suppl):S29-38. PubMed ID: 8822125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The establishment and validation of efficient assays for anti-IIa and anti-Xa activities of heparin sodium and heparin calcium.
    Suzuki T; Ishii-Watabe A; Hashii N; Nakagawa Y; Takahashi T; Ebisawa A; Nishi S; Fujita N; Bando A; Sekimoto Y; Miyata K; Endo T; Otsu T; Sugimoto S; Kondou T; Fujita Y; Miyanaga N; Mashimo M; Shimada N; Yoden H; Shimamura H; Kurata Y; Koyama S; Kawasaki N
    Biologicals; 2013 Nov; 41(6):415-23. PubMed ID: 24095600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma.
    Bendetowicz AV; Bara L; Samama MM
    Thromb Res; 1990 Jun; 58(5):445-54. PubMed ID: 2164262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparative study on the mechanism of the anticoagulant action of mollusc and mammalian heparins.
    Paiva JF; Santos EA; Jeske W; Fareed J; Nader HB; Dietrich CP
    Comp Biochem Physiol A Physiol; 1995 Jul; 111(3):495-9. PubMed ID: 7614042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity.
    Morris TA; Jacobson A; Marsh JJ; Lane JR
    Thromb Res; 2005; 115(1-2):45-51. PubMed ID: 15567452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
    Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo.
    Poli M; Asperti M; Ruzzenenti P; Mandelli L; Campostrini N; Martini G; Di Somma M; Maccarinelli F; Girelli D; Naggi A; Arosio P
    Biochem Pharmacol; 2014 Dec; 92(3):467-75. PubMed ID: 25241290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins.
    Young E; Cosmi B; Weitz J; Hirsh J
    Thromb Haemost; 1993 Oct; 70(4):625-30. PubMed ID: 8115988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Is there a difference between low-molecular-weight heparins?].
    Eritsland J
    Tidsskr Nor Laegeforen; 2005 Oct; 125(20):2802-3. PubMed ID: 16244685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.
    Linhardt RJ; Loganathan D; al-Hakim A; Wang HM; Walenga JM; Hoppensteadt D; Fareed J
    J Med Chem; 1990 Jun; 33(6):1639-45. PubMed ID: 2160537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
    Bara L; Trillou M; Mardiguian J; Samama M
    Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antithrombin III-Binding Site Analysis of Low-Molecular-Weight Heparin Fractions.
    Chen Y; Zhao J; Yu Y; Liu X; Lin L; Zhang F; Linhardt RJ
    J Pharm Sci; 2018 May; 107(5):1290-1295. PubMed ID: 29339133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.